Hummingbird Bioscience ^Competitor

Hummingbird Bioscience is a clinical-stage biotechnology company focused on precision therapies for challenging targets in oncology and autoimmunity. The company develops antibody-based therapeutics, including antibody-drug conjugates (ADCs), utilizing proprietary technologies to meet unmet medical needs. Hummingbird employs a systems biology and data science-driven approach to identify optimal therapeutic targets and mechanisms.

The company offers a Rational Antibody Discovery Platform that facilitates the identification and engineering of antibodies against difficult epitopes. Its Linker-Payload Technologies enhance the development of next-generation ADCs for better efficacy and safety. Hummingbird is also involved in executing global clinical trials to accelerate drug development and improve patient access.

Hummingbird's product pipeline includes clinical-stage candidates HMBD-001 and HMBD-002, which target validated cancer pathways. The company collaborates with academic and industry partners worldwide to advance its therapeutic candidates, aiming to provide effective treatments for patients with cancers and autoimmune diseases resistant to current therapies. In May 2021, Hummingbird raised $125 million in Series C financing to support its clinical programs.